Harvest One (TSXV:HVT) (“Harvest One” or the “Company”) is pleased to advise that it has appointed Grant Froese as new Chief Executive Officer of the Company effective July 3, 2018. Mr. Froese has also been appointed to the Board of Directors.

Mr. Froese joins Harvest One following a 38-year career with Canadian retail giant Loblaw Companies Limited (TSE:L), last serving as Chief Operating Officer. During his career at Loblaw, Grant led operations and merchandising at all levels and has had oversight of information technology, supply chain, digital/e-commerce businesses, marketing, and Loblaw’s industry-leading control brands.


“The Board is very excited to welcome Grant to the Harvest One team,” states Peter Wall, Chairman of Harvest One. “Grant’s leadership experience and operational capabilities will be a significant asset to the Company as we look to execute on our strategic vision. With Grant’s background and credentials, we are very pleased to have appointed one of Canada’s leading executives.”

“Harvest One is a unique opportunity to apply my experience to a complex business with a portfolio of brands in the emerging regulated cannabis industry,” Grant Froese commented. “Harvest One has a platform for success through its three distinct business units in Canada and internationally. We will continue to build Harvest One as a house of brands, aiming to bring the most sophisticated cannabis products to the global medical and recreational markets. I’m also pleased to be immediately strengthening the Harvest One team with the appointment of Andrew Kain, a skilled, trusted executive that I’ve had the pleasure of working with in the past.”

Along with the appointment of Mr. Froese comes Mr. Andrew Kain as the new Chief Operating Officer and General Counsel of the Company. Andrew is a lawyer by profession who brings almost 25 years of extensive corporate, financial and legal experience to Harvest One.  Andrew joins Harvest One from his previous position as founder and President of Windular Research and Technologies Inc. a privately held corporation that provides innovative renewable energy systems, consulting and advisory services to the global telecommunications industry.

The Company also announced today the grant of 8 million stock options under the Company’s incentive stock option plan to certain of the Company’s directors and officers.  Each stock option entitles the holder to purchase one common share at an exercise price of $0.77 for a period of five years following the grant date.

About Harvest One Cannabis Inc. (TSXV: HVT)
Harvest One is a global cannabis company focused on delivering high quality, innovative cannabis products and technology to regulated markets around the world. Shareholders have significant exposure to the entire cannabis value chain through three wholly owned operating subsidiaries: Horticultural arm and Canadian Licensed Producer United Greeneries Ltd., medical and pharmaceutical arm Satipharm AG in Switzerland and Dream Water Global, the Group’s consumer goods division. For more information please visit https://www.harvestone.com

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

For further information: Colin Clancy, Investor Relations, + 1 (877) 915-7934, cclancy@mmj.ca

Click here to connect with Harvest One (TSXV:HVT) for an Investor Presentation.

Source: www.newswire.ca

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less